Kirk Schultz, MD, British Columbia Children’s Hospital, Vancouver, Canada, comments on the use of machine learning to identify patterns of immune tolerance or of developing chronic graft-versus-host disease (GvHD) after stem cell transplantation (SCT) in the pediatric ABLE 1.0 study cohort. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.